Temporomandibular Joint and Muscle Disorders Pathophysiological Mechanisms Linking Comorbid Conditions (R01) | Apply Online

Frequently Asked Questions (FAQs)

What is the goal of NIH Funding Opportunity Announcement PA 07-150?

PA 07-150 invites R01 research proposals to identify the underlying causes and biological mechanisms that link temporomandibular joint and muscle disorders (TMJMDs) with other chronic conditions that frequently occur alongside them. The focus is on explaining why symptoms overlap across conditions at molecular, physiological, and behavioral levels, rather than simply reporting that comorbidity exists.

What type of grant mechanism is this opportunity using?

This announcement uses the NIH Research Project Grant (R01) mechanism, intended for full-scale, hypothesis-driven research projects with enough scope and depth to substantially advance understanding of disease mechanisms.

What are TMJMDs as described in the announcement?

TMJMDs are described as a complex group of disorders affecting one or more tissues in the temporomandibular joint and the facial muscles. They most commonly present as persistent facial muscle pain along with restricted and painful jaw movement.

What does the FOA mean by "comorbidity" in this context?

Comorbidity refers to TMJMD occurring alongside other chronic conditions. The FOA emphasizes that research should investigate shared pathways and mechanisms that could plausibly connect TMJMD with these other conditions, leading to overlapping symptom patterns such as chronic pain, sensory disturbances, fatigue, or functional impairments.

Which comorbid conditions are specifically mentioned?

The FOA lists examples of conditions that can co-occur with TMJMD, including fibromyalgia, atypical facial pain, trigeminal neuralgia, chronic fatigue syndrome, multiple chemical sensitivity, irritable bowel syndrome, complex regional pain syndrome, and migraine.

Are only pain-related overlaps of interest, or are other functional problems included too?

Other functional and sensory problems are explicitly included. The FOA notes that these disorders may be accompanied by difficulties involving speech, hearing, swallowing, balance, smell, and taste, as well as certain cardiovascular diseases.

Is the FOA looking for studies that simply document that TMJMD and other conditions co-exist?

No. The FOA explicitly seeks studies that go beyond documenting co-existence and instead test mechanistic explanations for shared biological pathways and symptom overlap.

Can a project focus on a comorbid condition rather than TMJMD itself?

Yes. Projects may be centered either on TMJMD or on one of the comorbid conditions, as long as the specific aims are designed to uncover mechanisms that connect the disorders rather than treating them as unrelated.

What is the main expectation for a competitive proposal under this FOA?

The central expectation is a well-justified, modern, mechanistic research plan explaining how TMJMD and a selected comorbid condition might be biologically connected, using interdisciplinary methods to test that connection and move beyond symptom correlation toward pathway-level (and potentially causal) understanding.

What kinds of research approaches does the FOA encourage?

The FOA stresses state-of-the-art multidisciplinary and interdisciplinary approaches. It signals that strong applications may integrate methods across areas such as pain biology, neuroscience, immunology, endocrinology, musculoskeletal research, behavioral science, genetics/genomics, imaging, and quantitative symptom phenotyping.

Does NIH expect a single project to solve the entire TMJMD comorbidity problem space?

No. The FOA notes that the overall problem is too broad for a single project to solve in full and encourages applicants to narrow their scope to a specific pathway and a particular comorbid disease relationship.

Does the FOA provide an example of how to narrow a research scope?

Yes. It suggests targeting a specific pathway while pairing it with a particular comorbid relationship, such as TMJMD and migraine or TMJMD and fibromyalgia, to develop a focused mechanistic explanation that can be tested rigorously.

Are there related NIH announcements for smaller or earlier-stage projects?

Yes. The FOA is presented as running in parallel with two other announcements of the same scientific scope but different mechanisms: an R03 option for small research projects (PA 06-267) and an R21 option for exploratory or developmental work (PA 06-268).

What does the existence of parallel R03 and R21 announcements imply?

It suggests NIH is supporting a pipeline of research from early, potentially high-risk ideas (R21) and smaller targeted efforts (R03) through to more comprehensive mechanistic studies (R01).

Are awards guaranteed under this opportunity?

No. The FOA states that awards depend on the availability of funds and the receipt of a sufficient number of meritorious applications.

Which CFDA program areas are associated with this FOA?

The opportunity falls under multiple CFDA areas reflecting its cross-cutting science: oral diseases and disorders research (93.121), deafness and communication disorders research (93.173), arthritis/musculoskeletal/skin diseases research (93.846), and neuroscience and neurological disorders extramural research (93.853).

What does the mix of CFDA areas suggest about NIH's view of TMJMD comorbidity research?

It reinforces that NIH views this research as spanning oral health, musculoskeletal biology, nervous system mechanisms, and communication-related functions, consistent with the broad symptom and functional impacts described in the FOA.

Who is eligible to apply?

Eligibility is broad and includes many types of domestic organizations such as universities, nonprofits, state and local governments, tribal governments and organizations, public housing authorities, and for-profit entities (including small businesses, with additional mention that for-profits other than small businesses are also eligible). The FOA also states that foreign institutions are eligible, eligible federal agencies may apply, and faith-based and community-based organizations may apply.

Are foreign institutions allowed to apply?

Yes. The FOA states that foreign institutions are eligible to apply.

Is there a cost-sharing or matching requirement?

No. The FOA states there is no cost-sharing or matching requirement.

When was this FOA posted, and is it still active?

The original posting date is listed as December 13, 2006, with multiple receipt dates and a last listed closing date of May 7, 2007. It is archived as of June 7, 2009, indicating it is no longer active, though it can still serve as a reference for NIH priorities and for structuring similar mechanistic comorbidity proposals.

What symptom patterns is the FOA especially interested in explaining?

The FOA emphasizes overlapping symptom patterns that may arise from shared mechanisms, including chronic pain, sensory disturbances, fatigue, and functional impairments, and it encourages research that can connect these patterns to molecular, physiological, and behavioral pathways.